CHEK1 and neuroblastoma: It has recently been identified as a lead therapeutic target in neuroblastoma [31], and prior work by the AstraZeneca research and development team identified CHK1 inhibition by AZD7762 as contributing to efficacy of DNA-damaging agents [20].